Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820175 | 0.90 | ALDH1A1 (0.33) | CYP2C19ALDH1A1POLBBLMATM | |
| SCHEMBL15412096 | 0.84 | ALDH1A1 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1972716 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL15412964 | 0.79 | HDAC3 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15412097 | 0.78 | ALDH1A1 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15634824 | 0.77 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14432755 | 0.76 | DGKA (0.46) | ALDH1A1 | |
| SCHEMBL6738571 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL731664 | 0.75 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL17204502 | 0.75 | DGKA (0.48) | HDAC11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175904-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11123416-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20190117754-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10034927-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3312158-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | The Brigham and Women's Hospital, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2315747-B1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20160375117-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9474806-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20140037633-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-02-06 | — | — | US | disclosed |
| US-8492364-B2 | Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110150880-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375117-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, B3GAT3, OGT | HDAC3 1781/4885HDAC4 3723/4885HDAC1 2781/4885 |
| US-20140037633-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, OGT, FUT5 | HDAC3 1900/4885HDAC4 3167/4885HDAC1 2140/4885 |
| US-20110150880-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, OGT, FUT5 | HDAC3 1900/4885HDAC4 3167/4885HDAC1 2140/4885 |
| US-10034927-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | FUT6, B3GAT3, OGT | HDAC3 1781/4885HDAC4 3723/4885HDAC1 2781/4885 |
| US-11123416-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | FUT6, B3GAT3, OGT | HDAC3 1781/4885HDAC4 3723/4885HDAC1 2781/4885 |
| US-20220175904-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, B3GAT3, OGT | HDAC3 1794/4885HDAC4 3768/4885HDAC1 2806/4885 |
| US-20190117754-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, OGT, FUT5 | HDAC3 1900/4885HDAC4 3167/4885HDAC1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.